1,150 results on '"Elisaf, M"'
Search Results
2. Effects of evolving lipid-lowering drugs on carbohydrate metabolism
3. Dipeptidyl peptidase-4 inhibitors and protection against stroke: A systematic review and meta-analysis
4. ARTERIAL STIFFNESS, ADHERENCE TO TREATMENT AND COGNITIVE FUNCTION WITH THE USE OF IRBESARTAN IN NEWLY DIAGNOSED HYPERTENSIVE PATIENTS
5. Gitelman syndrome: an analysis of the underlying pathophysiologic mechanisms of acid–base and electrolyte abnormalities
6. Phosphate imbalance in patients with heart failure
7. l-Carnitine/Simvastatin Reduces Lipoprotein (a) Levels Compared with Simvastatin Monotherapy: A Randomized Double-Blind Placebo-Controlled Study
8. Hyponatremia in patients with liver diseases: not just a cirrhosis-induced hemodynamic compromise
9. Comparative effect of valsartan-amlodipine treatment versus telmisartan-amlodipine treatment in HOMA-IR, HOMA-B, HOMA-S and QUICKI indexes in prediabetic hypertensive patients
10. Comparative effect of valsartan-amlodipine treatment versus telmisartan-amlodipine treatment in fasting glucose, fasting insulin, OGTT and HbA1c levels, in prediabetic hypertensive patients
11. Comparative effect of delapril-manidipine treatment versus valsartan-amlodipine treatment in fasting glucose, fasting insulin, OGTT and HbA1c levels, in prediabetic hypertensive patients
12. Comparative effect of delapril-manidipine treatment versus valsartan-amlodipine treatment in HOMA-IR, HOMA-B, HOMA-S and QUICKI indexes in prediabetic hypertensive patients
13. Comparative effect of delapril-manidipine treatment versus telmisartan-amlodipine treatment in HOMA-IR, HOMA-B, HOMA-S and QUICKI indexes in prediabetic hypertensive patients
14. Comparative effect of delapril-manidipine treatment versus telmisartan-amlodipine treatment in fasting glucose, fasting insulin, OGTT and HbA1c levels, in prediabetic hypertensive patients
15. No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population
16. Hypertriglyceridemia, remnant cholesterol and cardiovascular risk: what genes can say
17. Distinct effects of fixed combinations of valsartan with either amlodipine or hydrochlorothiazide on lipoprotein subfraction profile in patients with hypertension
18. High Doses of Rosuvastatin are Superior to Low Doses of Rosuvastatin Plus Fenofibrate or n-3 Fatty Acids in Mixed Dyslipidemia
19. The Effects of Ezetimibe and/or Orlistat on Triglyceride-Rich Lipoprotein Metabolism in Obese Hypercholesterolemic Patients
20. Serum uric acid is independently associated with hypertension in patients with rheumatoid arthritis
21. Ankle-brachial index long-term outcome after first-ever ischaemic stroke
22. Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome
23. Statins: another class of antihypertensive agents?
24. Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease
25. Comparison of switch to the highest dose of rosuvastatin vs. add-on nicotinic acid vs. add-on fenofibrate for mixed dyslipidaemia
26. Lysis syndrome during therapy of visceral leishmaniasis
27. Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome
28. Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance
29. Medication-induced hypophosphatemia: a review
30. Does intensive cholesterol lowering increase the risk of diabetes?
31. Cola soft drinks and hypokalaemia
32. Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose
33. Effects of orlistat, alone or combined with hypolipidemic drugs, on cardiovascular risk factors
34. Cola-induced hypokalaemia: pathophysiological mechanisms and clinical implications
35. ASSOCIATION BETWEEN TYPE D PERSONALITY AND THE METABOLIC SYNDROME
36. Blood pressure drug therapy and electrolyte disturbances
37. Sibutramine-associated adverse effects: a practical guide for its safe use
38. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis
39. Increased plasma visfatin levels in subjects with the metabolic syndrome
40. Ezetimibe-associated adverse effects: what the clinician needs to know
41. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis
42. Association of serum uric acid with cardiovascular disease in rheumatoid arthritis
43. Excess body weight and risk of first-ever acute ischaemic non-embolic stroke in elderly subjects
44. Different definitions of the metabolic syndrome and risk of first-ever acute ischaemic non-embolic stroke in elderly subjects
45. Statins for non-alcoholic fatty liver disease: a new indication?
46. The control of dyslipidemia in out Patlent clinics in Greece (OLYMPIC) Study
47. Diagnosis and management of the metabolic syndrome in obesity
48. Serum uric acid levels and risk for acute ischaemic nonembolic stroke in elderly subjects
49. Pathogenesis, detection and treatment of Achilles tendon xanthomas
50. Lack of association between carotid intima-media thickness and PAF-acetylhydrolase mass and activity in patients with primary hyperlipidemia: 90
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.